Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/40546
Title: Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: protocol for a randomized, placebo-controlled trial
Authors: Sprigg, Nikola
Robson, Katie
Bath, Philip
Dineen, Robert
Roberts, Ian
Robinson, Tom
Roffe, Christine
Werring, David
Al-Shahi Salman, Rustam
Pocock, Stuart
Duley, Lelia
England, Tim
Whynes, David
Ciccone, Alfonso
Laska, Ann C.
Christensen, Hanne
Ozturk, Serefnur
Collins, Ronan
Bereczki, Daniel
Egea-Guerrero, Juan J.
Law, Zhe K.
Czlonkowska, Anna
Seiffge, David
Beredzie, Maia
TICH-2 Investigators
First Published: 5-Apr-2016
Publisher: SAGE Publications
Citation: International Journal of Stroke, 2016, 11 (6), pp. 683-694
Abstract: RATIONALE: Outcome after intracerebral hemorrhage remains poor. Tranexamic acid is easy to administer, readily available, inexpensive, and effective in other hemorrhagic conditions. AIM: This randomized trial aims to test the hypothesis that intravenous tranexamic acid given within 8 h of spontaneous intracerebral hemorrhage reduces death or dependency. DESIGN: Phase III prospective double-blind randomized placebo-controlled trial. Participants within 8 h of spontaneous intracerebral hemorrhage are randomized to receive either intravenous tranexamic acid 1 g 10 min bolus followed by 1 g 8 h infusion, or placebo. SAMPLE SIZE ESTIMATES: A trial of 2000 participants (300 from start-up phase and 1700 from main phase) will have 90% power to detect an ordinal shift of the modified Rankin Scale with odds ratio 0.79. STUDY OUTCOMES: The primary outcome is death or dependency measured by ordinal shift analysis of the 7 level mRS at day 90. Secondary outcomes are neurological impairment at day 7 and disability, quality of life, cognition, and mood at day 90. Safety outcomes are death, serious adverse events, thromboembolic events, and seizures. Cost outcomes are length of stay in hospital, readmission, and institutionalization. DISCUSSION: This pragmatic trial is assessing efficacy of tranexamic acid after spontaneous intracerebral hemorrhage. Recruitment started in 2013; as of 15th January 2016 1355 participants have been enrolled, from 95 centers in seven countries. Recruitment is due to end in 2017. TICH-2 Trial is registered as ISRCTN93732214.
DOI Link: 10.1177/1747493016641960
ISSN: 1747-4930
eISSN: 1747-4949
Links: http://journals.sagepub.com/doi/10.1177/1747493016641960
http://hdl.handle.net/2381/40546
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2016, World Stroke Organization. Deposited with reference to the publisher’s open access archiving policy.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
TICH2protocolpaper_IJS_Revision15Jan.pdfPost-review (final submitted author manuscript)141.41 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.